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Abstract
A new patient with severe mucopolysaccharidosis (MPS) type VII is reported. Non-immune hydrops fetalis (NIHF) was
diagnosed during pregnancy. At birth, he showed generalized hydrops and dysmorphic features typical of MPS. Many
diagnoses were excluded before reaching the diagnosis of MPS VII at 8 months of life. During the first year of life he
had frequent respiratory infections associated with restrictive and obstructive bronchopneumopathy and underwent
three surgical interventions: decompression of the spinal cord at the craniocervical junction, bilateral inguinal hernia,
and bilateral clubfoot. At 14 months of life he underwent successful haematopoietic cell transplantation (HCT). During
the following 10 months, his bronchopneumopathy progressively worsened, needing chronic pharmacological
treatment and O2 administration. The patient died of respiratory insufficiency during a respiratory syncytial virus
infection at 25 months of age. Molecular analysis showed the homozygous variant c.1617C > T, leading to the
synonymous mutation p.Ser539=. This caused aberrant splicing with partial skipping of exon 10 (r.1616_1653del38) and
complete skipping of exon 9 (r.1392_1476del85; r.1616_1653del38). No transcript of normal size was evident. The
parents were both confirmed to be carriers. In a subsequent pregnancy, a prenatal diagnosis showed an affected fetus.
Ultrasound examination before abortion showed NIHF. The skin and placenta examination by electron microscopy
showed foamy intracytoplasmic vacuoles with a weakly electron-dense substrate. MPS VII is a very rare disease but it is
possible that some cases go undiagnosed for several reasons, including that MPS VII, and other lysosomal storage
diseases, are not included in the work-up for NIHF in many institutions, and the presence of anasarca at birth may be
confounding for the recognition of the typical facial characteristics of the disease. This is the eighth patient affected by
MPS VII who has undergone HCT. It is not possible to draw conclusions about the efficacy of HCT in MPS VII. Treatment
with enzyme replacement is now available and will probably be beneficial for the patients who have a milder form
with no or little cognitive involvement. Increased awareness among clinicians is needed for prompt diagnosis and to
offer the correct treatment as early as possible.
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Background
Mucopolysaccharidosis (MPS) type VII, or Sly syndrome
(MIM 253220), is a very rare, autosomal recessive, inherited
lysosomal storage disorder with an estimated overall
frequency between 1/300,000 and 1/2,000,000 [1]. It is
caused by deficiency of the lysosomal enzyme
β-glucuronidase (EC 3.2.1.31), which leads to the storage of
glycosaminoglycans (GAGs) dermatan sulfate, heparan sul-
fate, chondroitin sulfate in many tissues [2]. The gene en-
coding β-glucuronidase (GUSB; MIM# 611499) is 21 kb
long and contains 12 exons. The presence of unprocessed
multiple pseudogenes requires particular attention in diag-
nostic mutation analysis. To date, 64 different mutations
have been reported in the GUSB gene at the Human Gene
Mutation Database Professional (http://www.hgmd.org).
The phenotypic characteristics of MPS VII are re-
ported to be similar to those of MPS I and MPS II, al-
though non-immune hydrops fetalis (NIHF) is much
more frequent in MPS VII [3]. As of June 2016, accord-
ing to Montano et al. [1], there were 143 MPS VII pa-
tients described in the literature with a wide spectrum of
severity, from milder, late-onset forms with coarse facial
features, corneal clouding and frequent upper respira-
tory infections but mild skeletal abnormalities and nor-
mal intellectual performances, to the more severe forms
characterized by hydrops fetalis, short stature and severe
skeletal dysplasia, macrocephaly, ear infections, hepatos-
plenomegaly, hernias, and cognitive impairment.
Few single cases or small series were reported in the
literature until 2016 when Montano et al. reviewed the
clinical history of 56 patients collected all over the world
through a survey among medical specialists who had or
had previously had MPS VII patients under their charge
[1]. Among these patients, 23 (41%) had NIHF; 10 of
these showed a severe fetal-neonatal presentation with
early death while 13 survived longer, despite NIHF. Little
is known about the clinical history of the 10 patients
with early death who died prenatally or shortly after
birth. Of the 13 patients with history of hydrops and
longer survival, five patients received haematopoietic cell
transplantation (HCT) at an age between 7 months and
7 years and three of them have survived. Two other pa-
tients are reported who received HCT at the age of
11 months and 12 years and showed apparent benefit
2 years and 31 months after HCT, respectively [4, 5].
Here, we describe the clinical history of a new severe
case, from consanguineous healthy parents, who was
treated with HCT. The results of the prenatal diagnosis
of a second pregnancy of this couple are also shown.
Case presentation
First year of life
The proband is a male first child of first-degree cousin
parents from Pakistan (Punjabi ethnic origin). Fetal
ultrasound during pregnancy revealed a bilateral club-
foot and NIHF (hydrothorax + ascites). For this reason,
amniocentesis for karyotyping was performed and it gave
a normal result: 46,XY; maternal-fetal infections and
immune-haematological diseases were excluded.
The child was born by caesarean section at 32.5 weeks.
His weight was 3613 g (he had generalized oedema),
length was 52 cm, and cranial circumference was 36 cm
(SDs + 5.6, + 4.0, and + 4.4, respectively, according to
Olsen et al. [6]). The Apgar score was 4 at the first mi-
nute and the baby was intubated. He had respiratory
distress with bilateral hydrothorax that needed
right-side drainage for 12 days and mechanical venti-
lation for 8 days, ascites, and bilateral massive hydro-
cele. He also exhibited brachycephaly and bilateral
clubfoot. No infectious or haematological diseases
were seen in the baby. Figure 1 shows the infant at
20 days of life with a mildly coarse face and general-
ized oedema (Fig. 1a, b).
At 1 month of age, metabolic screening on the urine
showed normal free sialic acid (109 mmol/mol creatinine
with normal value < 123) while the conjugated and total
sialic acid were increased (811 mmol/mol creatinine
with normal value < 343 and 920 mmol/mol creatinine
with normal value < 454, respectively), and increased
GAGs (357 mg/g creatinine with normal value 5.9–60).
These results prompted the enzyme analysis on fibro-
blast culture for MPS I, MPS II, MPS IVA and IVB,
MPS VI, sialidosis, and mucolipidosis II, which were all
normal.
During the following few months, the clinical evalu-
ation showed worsening of the facial dysmorphism
(see Fig. 1c, d), persistence of hydrocele, brachyceph-
aly and bilateral clubfoot, pectus carinatum, gibbus,
hepatomegaly, bilateral inguinal hernias, and joint
stiffness; a restrictive chest wall deformity was ob-
served with very limited or absent expansion of the
cage and only diaphragmatic breathing. At 3 months
of age he had axial hypotonia (he did not hold his
head up), mild hypertonia in the upper limbs, and
moderate hypertonia in the lower limbs. At the same
age, heart and kidney functions were normal. Periodic
abdominal ultrasound examinations showed progres-
sive disappearance of ascites over 6 months. Brain
stem evoked potentials evidenced bilateral severe
hypoacusia while the ophthalmological evaluation was
normal.
The skeleton x-ray showed dysostosis multiplex. In par-
ticular, spine abnormalities (craniocervical junction malfor-
mation, wedge-shaped L3 and L4, kyphosis, and scoliosis),
oar ribs, hypoplasia of the inferior portion of the iliac
bones and flared iliac wings, and squat femurs were
seen (Fig. 2); brain magnetic resonance imaging
(MRI) showed enlargement of the subarachnoid
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spaces and ventriculomegaly with spinal canal stenosis
at the C1 level (Fig. 3). Growth curves of the patient
are presented in (Fig. 4).
All these findings, together with his clinical history,
supported the suspicion of MPS, and MPS VII was
eventually investigated. The enzymatic assay for
β-glucuronidase, performed in cultured fibroblasts, re-
vealed a β-glucuronidase activity of 22 nmol/h/mg
(normal value 200–600; residual activity 5.5%) and
confirmed the diagnosis of MPS VII.
Fig. 1 The MPS VII patient at 20 days of age (a, b), 3 months (c) and 8 months (d). Note ascites, hydrocele, and feet and face oedema (a, b), and
typical dysmorphic appearance of the facies at 3 and 8 months of age
Fig. 2 X-rays of an MPS VII infant at the age of 3 months (a–d) and 12 months (e, f) showing generalized skeletal dysplasia (dysostosis multiplex). The
pelvis (a) shows typical imaging features characterized by rounded iliac wings and inferior tapering of the ilia with an undeveloped acetabulum;
proximal epiphysis of the femurs are not ossified. The femurs (c) are short with hypoplastic epiphyses, similarly to the upper left limb (b) in which
cortical thinning, flared metaphysis, and metacarpal widening are also identifiable. The hand (b) and foot (d) are typically dysmorphic: broad and short
metacarpals and bullet-shaped phalanges. In the antero-posterior projection of the thorax (e), a marked thickening of the ribs is evident (oar shaped
ribs). In the latero-lateral projection of the dorsal and lumbar spine (f), the lumbar vertebral bodies from L2 to L5 are markedly wedge deformed with
anterior beaking aspect (arrows), and with angulation of the dorsal-lumbar tract
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During the first year of life, the patient had frequent re-
spiratory infections associated with wheezing and desatur-
ation and underwent three surgical interventions: at
5 months for decompression of the spinal cord at the cra-
niocervical junction, and at 10 and 12 months, respect-
ively, for bilateral inguinal hernia and bilateral clubfoot.
At 12 months, a Griffiths test showed mildly delayed
psychomotor development (general quotient 70).
Haematopoietic cell transplantation (HCT) and second
year of life
At 14 months, the patient underwent successful HCT
from an unrelated 5/6 human leukocyte antigen
(HLA)-matched cord blood unit (total nucleated cells
7.3 × 107/kg, CD34+ cells 1.83 × 105/kg). The condi-
tioning regimen included Busulfan and cyclophospha-
mide and graft-versus-host disease (GvHD) prophylaxis,
anti-thymocyte globulin (ATG), cyclosporine, and
methylprednisolone. Engraftment was achieved on day
31. The post-transplant course was complicated by rota-
virus gut infection, Staphylococcus aureus bacteraemia,
cytomegalovirus reactivation (the recipient was positive),
and acute grade III GvHD, which all resolved. Chimerism
had been continuously documented as 100% donor. He
made developmental improvements and started walking
independently at 20 months of life.
In the second year of life, he developed chronic pul-
monary insufficiency with polypnoea and wheezing, need-
ing chronic therapy with inhaled salbutamol and a
positive end-expiratory pressure (PEEP) mask. Frequent
acute exacerbations with deep desaturations were also ob-
served with fever and/or infections and treated with an in-
creased dosage of beta2 agonist plus anticholinergic
bronchodilator, corticosteroids, and O2 therapy. Airway
computed tomography (CT) scans at 13 and 20 months
of life were similar and showed a restricted rib cage with
multiple dystelectatic areas of the lungs and no tracheal
abnormalities. From 20 months of age (6 months after
transplantation) his maximum O2 saturation outside in-
fection was 93–94% with lower values during sleep; from
then on, he started chronic O2 administration at home
during the night. At month 9 after HCT he started chronic
betamethasone and O2 administration the whole day due
to worsening respiratory distress. At 11 months after trans-
plantation, the child had a new acute episode of respiratory
distress that required hospitalisation in the Paediatric In-
tensive Care Unit with intubation and mechanical ventila-
tion. Infection with respiratory syncytial virus was detected
and, unfortunately, his respiratory insufficiency did not im-
prove and he deceased at 25 months of age.
Molecular studies
DNA analysis of the proband identified the homozygous
genetic variant c.1617C >T, leading to the synonymous mu-
tation p.Ser539=. This nucleotide variation, generating a 5′
splice site (GT) in a non-canonical exonic position, had pre-
viously been reported as causing an aberrant partial skipping
of the exon 10 (r.1616_1653del38) in a compound heterozy-
gous patient [7]. To confirm the aberrant splicing, reverse
transcriptase polymerase chain reaction (RT-PCR) was
Fig. 3 Brain MRI of an MPS VII patient at 12 months acquired post-surgery. On MR T2-weighted images acquired on the axial plane (a, b) through
lateral ventricles and basal ganglia, enlargement of subarachnoid spaces and dilatation of the ventricular system are visible. On the sagittal plane (c)
the corpus callosum is thinned and dysmorphic (arrowheads), and at the C1–C2 level, a cervical canal stenosis is still detectable (arrow)
Fig. 4 Growth centiles of the MPS VII patient showing a progressive
decrease in height and weight and mild increase in
head circumference
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conducted on GUSB mRNA extracted from the proband’s
fibroblast culture. The RT-PCR and sequence analyses
showed the expected partial skipping of exon 10
(r.1616_1653del38) already reported by Yamada et al. [7]
and, in addition, an abnormal shorter product in which
complete skipping of exon 9 also occurred
(r.1392_1476del85;r.1616_1653del38). No transcript of nor-
mal size was evident. The parents were both carriers of the
c.1617C >T mutation.
Genetic counselling and pre-natal diagnosis
Based on the information provided during the genetic coun-
selling, the couple requested pre-natal diagnosis in a subse-
quent pregnancy. Chorionic villus sampling (CVS) was
performed. The molecular analysis revealed that the DNA
from the CVS carried the homozygous c.1617C >T variant,
as the affected proband. The couple decided to abort. At
18 weeks of gestation, ultrasound examination before abor-
tion showed fetal hydrops, skin oedema, bilateral pleural ef-
fusion, and thickness of the placenta. No structural
abnormalities of the fetal organs were observed and a nor-
mal volume of amniotic fluid was present. The skin and pla-
centa examination by electron microscopy showed the
presence of foamy cytoplasmic vacuoles with a weakly
electron-dense substrate (Fig. 5), in accordance with the lit-
erature [7, 8].
Discussion and conclusions
To our knowledge, this is the first report of an MPS VII pa-
tient ever diagnosed in Italy. However, the ethnic back-
ground of the patient was not European but Southern
Asian. Until now, only a subject with a pseudodeficiency of
the gene (Asp152Asn) is described with Italian origin in the
literature [9]. This variant, Asp152Asn, shows a European
allele frequency of 0.00172 versus that found in the Asian
(0.00006224), Latino (0.0003956), and African (0.000206)
populations, respectively (data from ExAC Browser Beta
http://exac.broadinstitute.org/). We suppose that MPS VII
is very rare in Italy, as in other countries in western Europe,
but attenuated cases might have been overlooked. MPS VII
is an ultra-rare disease and is probably less known and di-
agnosed than the other MPS types. [1]. Our patient was
tested for many other metabolic disorders before being
tested for MPS VII. It is possible that the presence of ana-
sarca in many MPS VII newborns may prevent recognition
based on the coarse facies and contributes to delayed diag-
nosis. As recently reported in a systematic review aiming to
evaluate the incidence of lysosomal storage disorders
(LSDs) in 54 case series of NIHF published from 1979
through January 2014 [10], LSDs were not tested in 72% of
the papers reporting work-up for NIHF. Nonetheless, there
are at least fourteen LSDs that are a possible cause of NIHF
[11] and among them MPS VII is the most frequent ac-
counting alone for 20% [10]. It is therefore evident that
MPS VII should be tested in all cases of NIHF, even
though it is an ultra-rare disease. The availability of new
techniques such as next-generation sequencing (NGS)
might help to improve the number of diagnoses in this
field; a specific NGS panel for NIHF, testing not only LSDs
but also the other metabolic disturbances known to be a
cause of NIHF, such as CDG syndromes, peroxisomal dis-
orders, disturbances of cholesterol metabolism, and
others, could be used as a first-line investigation technique
as recently proposed by Sudrié-Arnaud et al. [12].
According to the classification of Montano et al.
[1], the proband had the severe infantile form. He
Fig. 5 Electron microscopy of the skin (left) and placenta (right) of an 18-week MPS VII fetus, showing the presence of many foamy intracytoplasmatic
vacuoles with a weakly electron-dense substrate
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was able to recover from NIHF and also survived the
three surgical interventions performed in his first year
of life. His pulmonary involvement was severe and it
was the cause of his death. Reasonably, rather than a
consequence of his HCT, his bronchopneumopathy
can be interpreted as an expression of a chronic
bronchopulmonary disease, favoured by prematurity,
NIHF with pleural effusion, mechanical ventilation,
and chest wall deformities which prevented a normal
chest expansion. Interestingly, 71% of the patients in
the study of Montano et al. [1] had decreased pul-
monary function (both restrictive and obstructive);
they had thoracic deformities contributing to restrict-
ive airway disease, leading to chronic hypoventilation
with low forced vital capacity, but also individual pa-
tients were reported with severe pulmonary disease
(bronchopulmonary dysplasia with fibrosis), recurrent
pneumothoraces, interstitial lung disease, and pro-
longed oxygen dependency [1]. It appears that severe
bronchopulmonary involvement in MPS VII is similar
to that found in MPS II [13] but is probably more
frequent than in MPS I [14].
Seven MPS VII patients are described so far who have
undergone HCT (Table 1) [1, 4, 5]. Of these, two were
transplanted at a very late age (7 and 12 years). The age
of transplantation is not known for a third patient. The
outcome is available for three of the other four patients,
although only the short-term outcome for two of them.
Our patient is the eighth who was transplanted; he
underwent the procedure at a reasonable age and did
not have any initial severe adverse events. His clinical
picture was, however, dominated by the respiratory in-
sufficiency, which was probably multifactorial, and his
outcome was unfavourable. The data available are too
scarce, and the patients transplanted too few, to allow a
conclusion about the efficacy of HCT in MPS VII. Enzyme
replacement therapy (ERT), which has recently been ap-
proved by the Food and Drug Administration (FDA) in No-
vember 2017 for paediatric and adult patients with MPS VII
[15], seemed beneficial on the severe bronchopulmonary in-
volvement as reported for the first patient who underwent
ERT [16]; in the blind-start study recently performed on 12
subjects by Harmatz et al. [17], most patients could not be
tested for pulmonary function and, of the 2 who were tested,
one worsened and the other did not improve.
The major limitation of ERT for MPS is that it does
not cross the blood–brain barrier preventing any effect
on the central nervous system (CNS) in severely affected
patients who show cognitive involvement (see Concolino
et al. in this Supplement for details [18]).
The synonymous mutation (c.1617C >T; p.Ser539=), pre-
viously reported in a compound heterozygous patient [7], is
first described in the homozygous state in the present report.
In addition, the RT-PCR analysis on the proband’s sam-
ples provided new insights on the effect of the substitution
c.1617C > T, creating a non-canonical intra-exonic 5′
splice site (GT) on GUSB mRNA processing. Indeed, the
results revealed not only the presence of the previously
described shorter transcript with partial skipping of exon
10 [7], but also an additional shorter GUSB transcript in
which complete skipping of exon 9 occurred upstream of
the partial skipping of exon 10.
The ultrastructural appearance of the fetal tissues (Fig. 5)
with numerous cytoplasmic vacuoles was consistent with
previous findings in the literature [7, 8].
Over the last few years, the use of multiple diagnostic
NGS-based panels has become available for genetic disor-
ders. Therefore, in the near future, it is possible that NGS
techniques could help clinicians in performing earlier
diagnoses of ultra-rare diseases, a fundamental condition
for timely access of patients with a progressive disease to
therapies that offer hope for a better prognosis.
Table 1 Mucopolysaccharidosis VII patients reported in the literature who underwent HCT




Hydrops Age at HCT Post-HCT outcome Reference
1 F Birth 1 year
10 months
No 2 years (failed) and
4 years
Alive at 1 month [1]
2 M Unknown 2 years No After 7 years Died of complications from HCT [1]
3 M 4 months 4 monthsa No Unknown Died a few years after HCT (no follow-up data) [1]
4 M Prenatal 26 months Yes 3 years Moderate clinical phenotype at 15 years [1]
5 F Prenatal 2 weeks Yes 7 months Normal developmental milestones reached at 15 months [1]
6 F Birth Unknown No 11 months Well 2 years after HCT [4]
7 F Birth 1 month No 12 years Improvement of motor functions after 18 months. No
more ENT infections
[5]
8 M Prenatal 8 months Yes 14 months Died at 25 months of respiratory failure Present
study
ENT ear, nose, and throat, F female, HCT haematopoietic cell transplantation, M male
aPreviously affected sibling
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